Talk:EnteroMix

Comments left by AfC reviewers

• Comment: While I think this is otherwise fine to accept, it's too technical. The first line needs to at least say it's a therapeutic cancer vaccine, not a "multivirus oncolytic virotherapy", and explain why it got media attention. Wikipedia articles hould not be presented on the assumption that the reader is well-versed in the topic's field. See WP:NOT gilgongo (talk) 21:37, 11 January 2026 (UTC)

Thank you for your prompt review and for your comments on accessibility and clarity. I have revised the lead to make it more accessible to non-specialist readers by describing EnteroMix as an experimental cancer immunotherapy based on oncolytic viruses, and by explaining that its media attention was driven largely by viral social-media claims exaggerating its efficacy and clinical status, later examined by independent fact-checking organizations. I did not describe EnteroMix as a “therapeutic cancer vaccine” because this terminology originates from media mischaracterisation rather than from the biomedical literature, where oncolytic virus therapies are not classified as vaccines. Preserving this distinction is important, as the vaccine framing itself contributed to the spread of misleading public claims. The revised wording therefore aims to improve accessibility while maintaining scientific accuracy.Olgamatveeva (talk) 01:06, 12 January 2026 (UTC)

That's a bit better, but really the lead should be in an encyclopedic style for general readers (see WP:MTAU), with the rest of the article introducing the details without assuming too much knowledge. What's there right now is more of a technical (and overly detailed) overview followed by an even more technical breakdown.

I'm not a clinician, but I can try writing a more accessible lead based on my undertanding of the high-level characteristics. You can edit or revert it if it's not correct. gilgongo (talk) 08:51, 12 January 2026 (UTC)

Thank you for engaging in this and for working to make the lead more accessible (WP:MTAU). I fully agree with that goal and appreciate your attention to it, and I am very willing to continue improving the wording. However, I have restored the previous lead and revised it while we discuss possible improvements, because I have concerns about how several elements of your revised version align with the cited sources—particularly given that one of the article’s core purposes is to document media misinformation that was later examined by independent fact-checkers. Several elements of the revision may unintentionally echo the media mischaracterizations that the article's fact-checking sources were addressing. I think we should avoid repeating the same media mischaracterisations that originally drove the misinformation cycle around EnteroMix.

My specific concerns with your wording are:

1. Classification / terminology (source alignment): The revised lead describes EnteroMix as a generic “therapeutic cancer treatment” and then explains it as “training the immune system” to recognize malignant cells. The sources instead describe EnteroMix as an oncolytic virus–based approach (multivirus oncolytic virotherapy / oncolytic virus immunotherapy), which is conceptually different from the “training” language typically used for therapeutic cancer vaccines (e.g., neoantigen or mRNA vaccine platforms). Using vaccine-like mechanism language risks conflating EnteroMix with the separate “cancer vaccine” narrative present in media coverage.
2. Efficacy framing (WP:MEDRS / NPOV): The phrase “claims of high efficacy in early trials” reads as if there were trial-derived efficacy findings. As of late 2025, however, no published Phase I outcomes support such claims. The independent sources cited in the article specifically address exaggerated or misleading public claims about efficacy and clinical readiness. A biomedical lead should not present those claims without clear attribution and critical context.
3. Why it received media attention (critical context): The lead should make clear that the international attention was driven largely by viral social-media claims and media mischaracterisation (including “cancer vaccine” framing and “100% efficacy” language), which were later challenged by independent fact-checking organizations. Softening or removing that context risks making Wikipedia echo the misinformation rather than document it neutrally and critically.
4. Mechanism explanation (accuracy): “Training the immune system to recognize and destroy malignant cells” is not a neutral high-level description of oncolytic virotherapy. Oncolytic viruses are generally described as selectively infecting and lysing tumor cells while potentially stimulating secondary immune responses. This is a different mechanism framing than therapeutic vaccine language. If a mechanism sentence is retained in the lead, it should reflect how oncolytic virotherapy is described in reliable sources.
5. General limitations of oncolytic virotherapy (context for mechanism wording): In the biomedical literature, oncolytic virotherapy is widely recognized as experimentally challenging. Many candidate viruses fail to efficiently infect tumor cells, fail to replicate in vivo, or fail to generate a clinically meaningful immune response. As a result, during the last decade most Phase I/II oncolytic virus trials have not progressed to later-phase clinical success. For this reason, describing such therapies as reliably “training the immune system” risks overstating both mechanistic certainty and clinical effectiveness in a lead section.

For these reasons, I have temporarily reverted to the prior lead wording that (a) identifies EnteroMix as an experimental cancer immunotherapy based on oncolytic viruses and (b) explains that the media attention arose from viral claims later examined by independent fact-checking organizations.

I am very open to working toward a shorter, more accessible lead, but I think it should remain tightly anchored to the sourcing and avoid vaccine-style mechanism language or efficacy implications that are not supported by published clinical data.

I would welcome your thoughts on how we might best achieve that balance. Perhaps my revised version needs further inmprovmentOlgamatveeva (talk) 15:41, 12 January 2026 (UTC)

OK good, that's significantly more understandable now, I would say. A couple of things I would add in terms of compliance with MOS:LEAD:

1. It's not compulsory to cite statements in the lead, since these should be cited adequately in the body, unless those statements might be particularly controversial (which they don't seem to be). So I would simply remove them, making sure they are present to back up their expansion in the body text if needed (and of course linking non-common terms like "oncolytic" will be a good idea).
2. The lead is essentially so that readers can decide whether it's an an article they want to read. So in this case it can be quite short (althogh I would expect it to grow over time as events unfold). For example, I would remove details like "Phase I clinical trials, which primarily assess safety, dosage, and preliminary tolerability rather than effectiveness". Just leave it as "very early-stage clinical development" (and put the details of what that means in the body). And for the same reason, I would also be inclined to remove "According to its developers, EnteroMix is a mixture of four oncolytic viruses—replication-competent human enteroviruses including Coxsackievirus A21, Echovirus 7, Enterovirus B75, and a modified derivative of a Sabin poliovirus vaccine strain". It's enough for the reader to know that a mixture of four oncolytic viruses is involved. They are later named and explained in the body.

If what is left is an adequte, accessible summary of the primary points, then I think you'll have a good lead on what is otherwise quite a techncial article. So you may later expect other editors who may know more than me to perhaps simplify some of the wording in the body. gilgongo (talk) 16:56, 12 January 2026 (UTC)

Thank you again for the helpful MOS:LEAD guidance — I fully agree that the lead should be concise, accessible, and focused on key points to help readers decide if they want to continue. That said, one reason I've leaned toward including a brief mention of the very early clinical stage (Phase I, focused on safety) and the developers' public naming of the four oncolytic viruses is the unusually high level of public misinformation and hype surrounding EnteroMix. During research, I found widespread online claims of "100% efficacy," imminent availability as an approved treatment, or secrecy about the viral components — despite developers naming them (Coxsackievirus A21, Echovirus 7, Enterovirus B75, and a modified Sabin poliovirus strain) in interviews and sources, and the therapy remaining in very early testing with no proven efficacy yet. This has extended to some commercial websites marketing products as EnteroMix and implying FDA approval/readiness. A short, neutral statement in the lead — fully backed by reliable sources in the body — seems like a modest way to address persistent misunderstandings while keeping the summary accessible. I'm very open to simplifying further if the misinformation subsides or as more peer-reviewed data emerges. In the meantime, I'm happy to keep monitoring and updating the article with new reliable sourcing.Olgamatveeva (talk) 16:02, 13 January 2026 (UTC)

I see - no problem in that case. I would though tend to remove the citations in the lead (and they are duplicated in the body), since having them there sometimes encourages people to add statements not present in the body. gilgongo (talk) 08:33, 14 January 2026 (UTC)

And as I predicted - that's exactly what's happend. To discourage further lead bloat, I'll move the edit into the body and summarise in the lead as per MOS:LEAD.

I have also reduced repetitions about the absence of peer-reviewed evidence in several places in the interests of WP:NPOV. Yes, EnteroMix hasn't got anything outside of Russia, but to re-state that fact in almost every section is WP:UNDUE gilgongo (talk) 07:23, 17 January 2026 (UTC)

Thank youOlgamatveeva (talk) 00:14, 18 January 2026 (UTC)

Thank you again for your monotoring this article and constructive cleaning, with which I fully agree. However, I would like to ask why the following sentence was removed from the lead by an editor who registered solely to make this single edit:

“EnteroMix gained widespread international media attention in late 2025 following viral social-media claims of high efficacy, imminent availability, or even ‘cure’ status — claims that independent fact-checking organisations later showed to be exaggerated and misleading.”

This sentence is:

✔ Neutral in tone

✔ Clearly attributed to reliable secondary sources (AFP, Snopes, Newsweek, etc.)

✔ Balanced, presenting both the media claims and the subsequent fact-checking

✔ Consistent with WP:LEAD, which requires summarizing major aspects of public reception

✔ Required by WP:NPOV to reflect notable critical evaluation

✔ Supported by WP:V through independent verification

✔ Particularly important under WP:MEDRS to avoid the persistence of unsupported medical claims

The international media attention and subsequent fact-checking are a major part of EnteroMix’s public notability and therefore belong in the lead.

I also note that a similar fact-checking-related statement about EnteroMix was recently removed from the article Oncolytic virus by another newly registered account. While this may be coincidental, the pattern reinforces the importance of carefully preserving policy-compliant, well-sourced coverage of public reception and independent verification.

If there are concerns about wording, I am very open to refinement. I agree to remove citations from the lead. However, full removal of this aspect creates an imbalance in the article’s representation of EnteroMix’s public and scientific context. Olgamatveeva (talk) 01:14, 18 January 2026 (UTC)

It seems they replaced the international media attention point with the point about EnteroMix's lack of scientific scrutiny, which appears to be supported by the sources they gave. The assertion that international media attention and fact-checking are a major part of EnteroMix’s notability would seem to be WP:SYNTH, but I've re-instated the point. Adding a citation into the lead could be OK if a statement is likely to be contested, but on its face that doesn't seem to be the case to me. Again, part of the reason why citing statements in the lead is bad idea is that it encourages "drive by additions" from people who may be too lazy to incorporate them into the body, or worse, do so to distort the balance. The lead is not the article, but a summary of it. gilgongo (talk) 08:15, 18 January 2026 (UTC)

Thank you very much!Olgamatveeva (talk) 23:32, 18 January 2026 (UTC)

Feedback from New Page Review process

I left the following feedback for the creator/future reviewers while reviewing this article: Thank you for working carefully through the AfC process to build this article. While I'm rather cynical about the approach, you've included appropriate caveats and the article is clear; it's worth covering given that there has been sustained coverage in international media about this.

Klbrain (talk) 12:11, 21 April 2026 (UTC)

@Klbrain: Thank you for the review. I agree that the international media coverage makes this a notable topic, and I've worked to ensure the scientific caveats are represented accurately to maintain NPOV (Neutral Point of View). Thanks again for your help in the AfC process. ~~~~ Olgamatveeva (talk) 01:40, 22 April 2026 (UTC)

Concerns regarding repeated removal of sourced content

I am restoring the sentence regarding social media fact-checking. I have noted that on two separate occasions, Single-Purpose Accounts (SPA) have deleted this neutrally phrased, content without explanation. This pattern of removing documented controversy suggests a [[WP:COI]] (Conflict of Interest) aimed at sanitizing the article. Per [[WP:LEAD]] and [[WP:NPOV]], the article must reflect the critical coverage and "hype" documented by independent organizations. Please discuss any further removals here on the talk page rather than deleting it. Olgamatveeva (talk) 01:38, 22 April 2026 (UTC)